CAR-T To Go: Juno Sees JCAR017 As Safer, Suited For Outpatients
Executive Summary
Data for JCAR017 in diffuse large B-cell lymphoma to be presented at the upcoming ASH meeting suggest that the therapy has best-in-class safety and efficacy, paving the way for use outside major medical centers, a potential competitive advantage.
You may also be interested in...
J.P. Morgan Notebook Day 3: Lilly's CGRP Prospects, Juno On Track, Color From Alnylam's Greene, Shire's New CMO
Daily round-up of news and notes from the 2018 J.P. Morgan Healthcare Conference in San Francisco: Lilly CEO on CGRP reimbursement jitters, Alnylam president on Sanofi deal terms, Juno stakes BCMA myeloma claim, Shire's new CMO.
J.P. Morgan Notebook Day 3: Lilly's CGRP Prospects, Juno On Track, Color From Alnylam's Greene, Shire's New CMO
Daily round-up of news and notes from the 2018 J.P. Morgan Healthcare Conference in San Francisco: Lilly CEO on CGRP reimbursement jitters, Alnylam president on Sanofi deal terms, Juno stakes BCMA myeloma claim, Shire's new CMO.
The Next Challenge: Improving And Predicting Responses As CAR-T Therapies Advance
Chimeric antigen receptor T cell (CAR-T) therapies have shown unprecedented response rates and may extend survival for patients expected to live only a few more months. Now, CAR-T developers are looking at how to improve responses, extend survival and improve safety.